Join us at #ACMG2025 We will be showcasing our upcoming rare disease products in our showcase, Advancing Rare Disease Diagnostics, on March 19th at 12:15 PM PST. Lunch will be provided. Register here: lnkd.in/gP847QVR

Our next roundtable covers the challenges & strategies for integrating vast, multi-modal datasets into their clinical testing workflows. hello.dnanexus.com/webinar/inno... @dcgenomics.bsky.social @labcorp.bsky.social @premalshah.bsky.social h.bsky.social @myome.com

Today we are excited to launch CAD iPRS — a cutting-edge, genome-wide polygenic risk score for coronary artery disease. Empowering primary care to identify high-risk patients and personalize prevention strategies. Read more here: prnewswire.com/news-release...

MyOme’s Dr. Akash Kumar will speak at WashU Medicine’s Rare Disease Day event on: 📅 Feb 20 | 1:45PM PT / 3:45PM CT 🧬 Shortening Diagnostic Timelines for Rare Diseases – A Whole-Genome Platform Approach

Join our discussion on clinical testing innovations that are enabling organizations to derive insights into #oncology & #raredisease. hello.dnanexus.com/webinar/inno... @dcgenomics.bsky.social @labcorp.bsky.social @premalshah.bsky.social @myome.com

We're partnering with Novi Health to bring whole genome testing to employer health programs. Through this collaboration, employees and their families gain access to whole genome sequencing, integrated risk (with PRS) reports, and expert genetic counseling. prn.to/4jzWF7T

MyOme's CEO, Premal S. Shah, PhD, is excited to speak at #PMWC2025 on Feb 6 at 2 PM. We'll discuss integrated polygenic risk scores for breast cancer & coronary artery disease. Learn more: pmwcintl.com/program/ #PrecisionMedicine

Big news! 🧬 Natera & MyOme launch iPRS™, a personalized tool to assess breast cancer risk. Backed by research, iPRS integrates >1M genetic markers & clinical inputs for accurate, cross-ancestry insights. Learn more: ow.ly/mGsJ50UntLt #BreastCancer #Genetics